|December 17, 2002
|Hemispherx to Host Conference Call on Recent Presentation at the 2002 DART Conference and Other Recent Developments
| Call Scheduled for Wednesday, December 18, 2002 at 11:00 AM Eastern Standard Time
Philadelphia, PA, Tuesday, December 17, 2002: -- Hemispherx Biopharma, Inc. HEB, a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, announced today that it will be hosting a conference call on Wednesday, December 18, 2002 at 11:00 AM Eastern Standard Time.
During the call the Company will discuss the Data presented by Dr. Gary Blick, Chief Independent Clinical Investigator for the Company's Phase IIb Trials for HIV/AIDS. It will also discuss recent developments in the treatment of HIV/AIDS as these developments relate to the Company's technology and it will describe other recent development regarding the U.S. Government funded trials, the completion of enrollment of the Company's Phase III trial for Chronic Fatigue Syndrome and the overall status of the company. Dr. William Carter, President and CEO of Hemispherx, and Dr. Gary Blick will lead the call.
In order to participate in this conference call, please call (800) 915-4836 in the U.S. and Canada, and 011 197 331 753 19 if outside those countries, and ask for the operator. Inform the operator that the leader is Wesley Stanton and give your name and verbal pass code which is Hemispherx.
It is suggested you please place your call no later then 10:50 a.m. on Wednesday morning. Due to the overwhelming response to our last conference call, please submit all questions prior to the call and they will be addressed during the last 15 minutes of the presentation. To submit a question, please email email@example.com or fax them to (212) 495-0746, Attention: Wesley Stanton, Regarding: Hemispherx Conference Call.
Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, you can visit the corporate website at http://www.hemispherx.net.
Hemispherx Biopharma, Inc., Investor Relations
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Wesley Stanton, MRB Institutional Investors, MRB
(212) 495-0200, Fax: (212) 495-0746
Robin Wagge, Rubenstein Associates, Inc.
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements